Advertisement
Advertisement
U.S. markets close in 4 hours 31 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Replimune Group, Inc. (REPL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
23.08-0.01 (-0.04%)
As of 11:28AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
MACD

MACD

Previous Close23.09
Open23.26
Bid22.86 x 800
Ask22.93 x 1200
Day's Range21.25 - 23.27
52 Week Range13.05 - 30.89
Volume350,636
Avg. Volume336,188
Market Cap1.148B
Beta (5Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for REPL

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Replimune Group, Inc.
    Daily – Vickers Top Buyers & Sellers for 03/17/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 months agoArgus Research
View more
  • Benzinga

    Replimune Shares Surge After Early Data From Pretreated Melanoma Patients

    Replimune Group Inc (NASDAQ: REPL) announced initial data from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical evaluating RP1 (vusolimogene oderparepvec) combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab). The overall response rate (ORR) was 36%, and the complete response (CR) rate was 20% compared to the 12.5% shown in the prior 16 patients presented in June 2022. Safety data with RP1 + nivolumab continues to demonstrate an att

  • Benzinga

    Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts

    BMO Capital Markets raised the price target on Replimune Group Inc (NASDAQ: REPL) to $40 from $30 on a bullish view into upcoming data readouts for lead asset RP1 in melanoma and cutaneous squamous cell carcinoma (CSCC). The analyst says robust safety and clinical benefit would give confidence in RP1 in earlier lines of treatment and earlier assets, RP2 and RP3. The analyst expects RP2 updates later this year for the monotherapy and RP2+Opdivo combo. RP3+Opdivo combo initial data is also expecte

  • Motley Fool

    Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

    U.S. stock markets have been exceedingly volatile in 2022. The billionaire brothers Julian and Felix Baker -- co-owners of the biotechnology focused hedge fund Baker Bros. Advisors -- are a prime example. Perhaps most interestingly, the Baker brothers bought large chunks of small-cap healthcare stocks Affimed (NASDAQ: AFMD), Cerus Corporation (NASDAQ: CERS), and Replimune Group (NASDAQ: REPL) in the most recent quarter.

Advertisement
Advertisement